Clinical trial: Renzapride treatment of women with irritable bowel syndrome and constipation - A double-blind, randomized, placebo-controlled, study
Lembo, A. J., Cremonini, F., Meyers, N., & Hickling, R. (2010) Alimentary…
Clinical trial: Renzapride therapy for constipation-predominant irritable bowel syndrome– multicenter, randomized, placebo-controlled, double-blind study in primary healthcare setting
George AM, Meyers NL & Hickling RI. (2008) Aliment Pharmacol Ther; 27:…
Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome
Tack, J., Middleton, S. J., Horne, M. C., Piessevaux, H., Bloor, J. S.,…
Atlantic Healthcare Supports Rare Disease Day
Cambridge, UK; 26th February 2021 Atlantic Healthcare plc (“Atlantic…
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome
Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D & Thomforde,…
Atlantic Healthcare to attend WuXi Global Forum, January 11-13th 2021
Cambridge, UK; 8th January 2021 Toby Wilson Waterworth (CEO) and David Bennett…
Atlantic Healthcare invited to attend the JP Morgan Healthcare Conference 2021
Cambridge, UK; 8th January 2021 Atlantic Healthcare plc will be attending the…
Featured in Nature magazine…. A lower risk, higher value, late stage pipeline for gastrointestinal diseases
Atlantic Healthcare plc featured in December 2020 biopharmadealmakers…
Atlantic Healthcare plc appoints pharmaceutical industry veteran Allan Cambridge to the Board of Directors
Cambridge, UK; 19th November 2020. Atlantic Healthcare plc (Atlantic…
Atlantic Healthcare supports World IBD Day
Cambridge, UK; May 19, 2020. Atlantic Healthcare plc (“Atlantic Healthcare” or…